From the study of tumor cell immunogenicity to the generation of antitumor cytotoxic cells in non-Hodgkin's lymphomas

Leukemia and Lymphoma

Volumn 38, Issue 3-4, 2000, Pages 247-263

  Chaperot, Laurence ^a   Jacob, Marie Christine ^a   Molens, Jean Paul ^a   Manches, Olivier ^a   Bensa, Jean Claude ^a   Plumas, Joël ^a  

^a Lab d'Immunol ETS Isere et Savoie   (France)

Author keywords

Adhesion molecules; Costimulation; Cytolysis; Immunogenicity; Non Hodgkin's lymphoma

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2;

ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; IMMUNOGENICITY; LYMPHOKINE ACTIVATED KILLER CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNOLOGY;

EID: 0034025588     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009087016     Document Type: Review

References (119)

1. Heslop, H.E. and Rooney, C.M. (1997) Adoptive cellular immunotherapy for EBV lymphoproliferative diseases. Immunol Rev, 157, 217-222.
2. Hsu, F.J., Benike, C., Fagnoni, F., Liles, T.M., Czerwinski, D., Taidi, B., Engleman, E. G. and Levy, R. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med, 2, 52-58.
3. Nestle, F.O., Alijagic, S., Gillet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G. and Schadendorf, D. (1998) Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Medicine, 4, 328-332.
4. Höltl, L., Rieser, C., Papesh, C., Ramoner, R., Bartsch, G. and Thurnher, M. (1998) CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal cell cancer. Lancet, 352, 1358-1358.
5. Krieger, J.I., Grammer, S.F., Grey, H.M. and Chesnut, R.W. (1985) Antigen presentation by splenic B cells: resting B cells are ineffective, whereas activated B cells are effective accessory cells for T cell responses. J. Immunol. 135, 2937-2945.
6. Villacres Eriksson, M. (1995) Antigen presentation by naive macrophages, dendritic cells and B cells to primed T lymphocytes and their cytokine production following exposure to immunostimulating complexes. Clin Exp Immunol, 102, 46-52.
7. Liu, Y.J., Barthelemy, C., de Bouteilleer, O., Arpin, C., Durand, I. and Banchereau, J. (1995) Memory B cells from human tonsils colonize mucosal epithelium and directly present antigen to T cells by rapid up-regulation of B7-1 and B7-2. Immunity, 2, 239-248.
8. Milich, D.R., Chen, M., Schodel, F., Peterson, D.L., Jones, J.E. and Hughes, J.L. (1997) Role of B cells in antigen presentation of the hepatitis B core. Proc Natl Acad Sci U S A, 94, 14648-53.
9. Constant, S. (1999) B lymphocytes as antigen-presenting cells for CD4+ T cell priming in vivo. J. Immunol, 162, 5695-5703.
10. Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K.C., Cleary, M.L., Delsol, G., Dewolfpeeters, C., Falini, B., Gatter, K.C., Grogan, T.M., Isaacson, P.G., Knowles, D.M., Mason, D.Y., Mullerhermelink, H.K., Pileri, S.A., Piris, M.A., Ralfkiaer, E. and Warnke, R.A. (1994) A revised european-american classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood, 84, 1361-1392.
11. Makgoba, M.W., Sanders, M.E. and Shaw, S. (1989) The CD2-LFA-3 and LFA-1-ICAM pathways: relevance to T-cell recognition, Immunol Today, 10, 417-422.
12. Springer, T.A. (1990) Adhesion receptors of the immune system. Nature, 346, 425-434.
13. Clark, E.A. and Ledbetter, J.A. (1994) How B cells and T cells talk to each other. Nature, 367, 425-428.
14. Tohma, S., Hirohata, S. and Lipsky, P.E. (1991) The role of CD11a/CD18-CD54 interactions in human T cell dependent B cell activation. J Immunol. 146, 492-499.
15. Le Guiner, S., Le Dréan, E., Labarrière, N., Fonteneau, J.-F., Viret, C., Diez, E. and Jotereau, F. (1998) LFA-3 co-stimulates cytokine secretion by cytotoxic T lymphocytes by providing a TCR-independent activation signal. Eur. J. Immunol, 28, 1322-1331.
16. Koopman, G., Keehnen, R.M.J., Lindhout, E., Newman, W., Shimizu, Y., Van Seventer, G.A., De Groot, C. and Pals, S.T. (1994) Adhesion through LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J. Immunol. 152, 3760-3767.
17. Shaw, S., Luce, G.E., Quinones, R., Gress, R.E., Springer, T.A. and Sanders, M.E. (1986) Two antigen-independant pathways used human cytotoxic T-cell clones. Nature, 323, 262-264.
18. Jansen, J.H., Van der Harst, D., Wientjens, G.-J. H.M., Kooy-Winkelaar, Y.M.C., Brand, A., Willemze, R. and Kluin-Nelemans, H.C. (1992) Induction of CD1 la/leucocyte function antigen-1 and CD54/intercellular adhesion molecule-1 on hairy cell leukemia cells is accompanied by enhanced susceptibility to T-cell but not lymphokine-activated killer-cell cytotoxicity. Blood, 80, 478-483.
19. Altomonte, M., Gloghini, A., Bertola, G., Gasparollo, A., Carbone, A., Ferrone, S. and Maio, M. (1993) Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res, 53, 3343-8.
20. Foreman, N.K., Rill, D.R., Coustan, S.E., Douglass, E.C. and Brenner, M.K. (1993) Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication. Br J Cancer, 67, 933-8.
21. Jacob, M.-C., Agrawal, S., Chaperot, L., Giroux, C., Gressin, R., Le Marc'Hadour, F., Fabre, M., Sotto, J.-J., Bensa, J.-C. and Plumas, J. (1999) Quantification of cellular adhesion molecules (CAMs) on malignant B cells from non-Hodgkin's lymphoma. Leukemia, 13, 1428-1433.
22. Chaperot, L., Jacob, M.-C., Le Vacon, F., Giroux, C., Molens, J.-P., Sotto, J.-J., Bensa, J.-C. and Plumas, J. (1997) Relationships between susceptibility to LAK cell-mediated lysis, conjugate formation and adhesion molecules expression in non Hodgkin's lymphomas. Leukemia and Lymphoma, 28, 133-143.
23. Qian, F., Vaux, D.L. and Weissman, I.L. (1994) Expression of the integrin α4ß1 on melanoma cells can inhibit the invasive stage of metastasis formation. Cell. 77, 335-347.
24. Moller, P. and Hammerling, G.J. (1992) The role of surface HLA-A,B,C molecules in tumour immunity. Cancer Surv, 13, 101-27.
25. Shieh, D.-C., Gammon, M.C., Zweering, H.J. and Kao, K.J. (1996) Functional significance of varied quantitative and qualitative expression of HLA-A2.1 antigens in determining the susceptibility of cells to cytotoxic T lymphocytes. Human Immunol, 46, 18-26.
26. Rivoltini, L., Barracchini, K.C., Viggiano, V., Kawakami, Y., Smith, A., Mixon, A., Restifo, N.P., Topalian, S.L., Simonis, T.B., Rosenberg, S.A. and Marincola, F.M. (1995) Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res, 55, 3149-3157.
27. Torres, M.J., Ruizcabello, F., Skoudy, A., Berrozpe, G., Jimenez, P., Serrano, A., Real, F.X. and Garrido, F. (1996) Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens, 47, 372-381.
28. Hiraki, A., Kaneshige, T., Kiura, K., Ueoka, H., Yamane, H., Tanaka, M. and Harada, M. (1999) Loss of HLA haplotype in lung cancer cell lines: implications for immunosurveillance of altered HLA class I/II phenotypes in lung cancer. Clin Cancer Res, 5, 933-936.
29. Wang, Z., Margulies, L., Hicklin, D.J. and Ferrone, S. (1996) Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class i antigen expression. Tissue Antigens, 47, 382-390.
30. Perez, B., Benitez, R., Fernandez M.A., Oliva, M.R., Soto, J.L., Serrano. S., Lopez Nevot, M.A. and Garrido, F. (1999) A new beta2 microglobulin mutation found in a melanoma tumor cell line. Tissue Antigens, 53, 569-572.
31. Benitez, R., Godelaine, D., Lopez Nevot, M.A., Brasseur, F., Jimenez, P., Marchand, M., Oliva, M.R., van Baren, N., Cabrera, T., Andry, G., Landry, C., Ruiz Cabello, F., Boon, T. and Garrido, F. (1998) Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens, 52, 520-529.
32. Weiss, S. and Bogen, B. (1989) B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc. Natl. Acad. Sci. USA, 86, 282-286.
33. Jacob, M.C., Masson, D., Plumas, J., Chaperot, L., Favre, M., Gressin, R. and Bensa, J. C. (1997) Analysis of HLA-1 defects on the surface of malignant lymphoma B-cells (B-NHL) by CMF (Abstract). A.C. Pathol, 14, 188.
34. Amiot, L., Onno, M., Lamy, T., Dauriac, C., Le Prise, J.-Y., Fauchet, R. and Drenou, B. (1998) Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course. Br. J. Haematol, 100, 655-663.
35. Möller, P., Herrmann, B., Moldenhauer, G. and Momburg, F. (1987) Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high grade malignancy. Int. J. Cancer, 40, 32-39.
36. Plumas, J., Chaperot, L., Jacob, M.C., Giroux, C., Mollens, J.P., Sotto, J.J. and Bensa, J.C. (1995) Malignant B lymphocytes induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures. Eur. J. Immunol, 25, 3332-3341.
37. Garban, F., Truman, J.P., Lord, J., Drenou. B., Plumas, J., Jacob, M.C., Sotto, J.J., Charron, D. and Mooney, N. (1998) Signal transduction via human leucocyte antigen class II molecules distinguishes between cord blood, normal, and malignant adult B lymphocytes. Exp Hematol, 26, 874-884.
38. Pazmany, L., Mandelboim, O., Valesgomez, M., Davis, D.M., Reyburn, H.T. and Strominger, J.L. (1996) Protection from natural killer cell-mediated lysis by HLA-G expression on target cells. Science, 274, 792-795.
39. Rajagopalan, S. and Long, E.O. (1999) A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med, 189, 1093-1100.
40. Le Gal, F.A., Riteau, B., Sedlik, C., Khalil Daher, I., Menier, C., Dausset, J., Guillet, J. G., Carosella, E.D. and Rouas Freiss, N. (1999) HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol, 11, 1351-1356.
41. Paul, P., Rouas Freiss, N., Khalil Daher, I., Moreau, P., Riteau, B., Le Gal, F.A., Avril, M.F., Dausset, J., Guillet, J.G. and Carosella, E.D. (1998) HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A. 95, 4510-4515.
42. Paul, P., Cabestre, F.A., Le Gal, F.A., Khalil Daher, I., Le Danff, C., Schmid, M., Mercier, S., Avril, M.F., Dausset, J., Guillet, J.G. and Carosella, E.D. (1999) Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res, 59, 1954-1960.
43. Real, L.M., Cabrera, T., Collado, A., Jimenez, P., Garcia, A., Ruiz Cabello, F. and Garrido, F. (1999) Expression of HLA G in human tumors is not a frequent event. Int J Cancer, 81, 512-518.
44. Amiot, L., Onno, M., Renard, D., Drenou, B., Guillaudeux, T., Le Bouteiller, P. and Fauchet, R. (1996) HLA-G transcription studies during the different stages of normal and malignant hematopoiesis. Tissue Antigens, 48, 609-614.
45. Van den Eynde, B. and Bruggen, V.d. (1997) T cell defined tumor antigens. Curr. Opin. Immunol, 9, 684-693.
46. Stevenson, F.K., Zhu, D., King, C.A., Ashworth, L.J., Kumar, S. and Hawkins, R.B. (1995) Idiotypic DNA vaccines against B-cell lymphoma. Immunol Rev, 145, 211-228.
47. Terness, P., Welschof, M., Moldenhauer, G., Jung, M., Moroder, L., Kirchhoff, F., Kipriyanov, S., Little, M. and Opelz, G. (1997) Idiotypic vaccine for treatment of human B-cell lymphoma - Construction of IgG variable regions from single malignant B cells. Hum Immunol, 56, 17-27.
48. Chambost, H., Van Baren, N., Brasseur, F., Godelaine, D., Theate, I., Spagnoli, G.C., Xerri, L., Plumas, J., Michel, G., Coulie, P. and Olive, D. (Submitted) Expression of gene MAGE-A4 In Reed Sternberg cells.
49. Vonderheide, R.H., Hahn, W.C., Schultze, J.L. and Nadler, L.M. (1999) The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity, 10, 673-679.
50. Whang-Peng, J., Knutsen, T., Jaffe, E.S., Steinberg, S.M., Raffeid, M., Zhao, W.P., Duffey, P., Condron, K., Yano, T. and Longo, D.L. (1995) Sequential analysis of 43 patients with non-hodgkin's lymphoma: clinical correlations with cytogenetic, histologic, immunophenotyping, and molecular studies. Blood, 85, 203-216.
51. Mannering, S.I., McKenzie, J.L., Fearnley, D.B. and Hart, D.N.J. (1997) HLA-DR1-restricted bcr-abl (b3a2.)-specific CD4(+) T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. Blood, 90, 290-297.
52. Nieda, M., Nicol, A., Kikuchi, A., Kashiwase, K., Taylor, K., Suzuki, K., Tadokoro, K. and Juji, T. (1998) Dendritic cells stimulate the expansion of bcr-abl specific CD8(+) T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood, 91, 977-983.
53. Freeman, G.J., Freedman, A.S., Segil, J.M., Lee, G., Whitman, J.F. and Nadler, L.M. (1989) B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J. Immunol, 143, 2714-2722.
54. Freeman, G.J., Gribben, J.G., Boussiotis, VA., Ng, J.W., Restivo, VA., Lombard, L. A., Gray, G.S. and Nadler, L.M. (1993) Cloning of B7-2 - a CTLA-4 counter-receptor that costimulates human T-Cell proliferation. Science, 262, 909-911.
55. June, C., Ledbetter, J., Linsley, P. and Thompson, C. (1990) Role of the CD28 receptor in T cell activation. J. Immunol, 11, 211-216.
56. Norton, S., Zuckerman, L., Urdahl, K., Shefner, R., Miller, J. and Jenkins, M. (1992) The CD28 ligand, B7, enhances IL-2 production by providing a costimulatory signal to T cells. J. Immunol, 149, 1556-1561.
57. Noel, P.J., Boise, L.H., Green, J.M. and Thompson, C.B. (1996) CD28 costimulalion prevents cell death during primary T cell activation. J Immunol, 157, 636-642.
58. Radvanyi, L.G., Shi, Y.F., Vaziri, H., Sharma, A., Dhala, R., Mills, G.B. and Miller, R. G. (1996) CD28 costimulation inhibits TCR-induced apoptosis during üprimary 1 cell response. J Immunol, 156, 1788-1798.
59. Walunas, T.L., Bakker, C.Y. and Bluestone, J.A. (1996) CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med, 183, 2541-2550.
60. Walunas, T.L., Lenschow, D.J., Bakker, C.Y., Linsley, P.S., Freeman, G.J., Green, J. M., Thompson, C.B. and Blueslone. J.A. (1994) CTLA-4 can function as a negative regulator of T cell activation. Immunity, 1, 405-413.
61. Lee, K.-M., Chuang, E., Griffin, M., Khattri, R., Hong, D.K., Zhang, W., Straus, D., Samelson, L.E., Thompson, B.C. and Bluestone, J.A. (1998) Molecular bases of T cell inactivation by CTLA-4. Science, 282, 2263-2266.
62. Fraser, J.H., Rincon, M., McCoy, K.D. and Le Gros, G. (1999) CTLA4 ligation attenuates AP-1, NFAT unit NF-kappaB activity in activated T cells. Eur J Immunol, 29, 838-844.
63. Koulova, L., Clark, E.A., Shu, G. and Dupont, B. (1991) The CD28 ligand B7/BB1 provides costimularory signal for alloactivation of CD4+ T cells. J. Exp. Med, 173, 759-762.
64. Azuma, M., Cayabyab, M.N., Buck, D., Phillips, J.H. and Lanier, L.L. (1992) CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J. Exp. Med. 175, 353-360.
65. Schultze, J.L., Cardoso, A.A., Freeman, G.J., Seamon, M.J., Daley, J., Pinkus, G.S., Gribben, J.G. and Nadler, L.M. (1995) Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc. Natl. Acad. Sci. USA, 92, 8200-8204.
66. Chaperot, L., Plumas, J., Jacob, M.-C., Bost, F., Molens, J.-P., Sotto, J.-J. and Bensa, J.-C. (1999) Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas. Exp. Hematol, 27, 479-488.
67. Vyth Dreese, F.A., Boot, H., Dellemijn, T.A., Majoor, D.M., Oomen, L.C., Laman, J. D., Van Meurs, M., De Weger, R.A. and De Jong, D. (1998) Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma. Immunology, 94, 580-586.
68. Vyth-Dreese, F.A., Dellemijn, T.A.M., Majoor, D. and de Jong, D. (1995) Localization in situ of the co-stimulatory molecules B7.1, B7.2, CD40 and their ligands in normal lymphoid tissue. Eur. J. Immunol, 25, 3023-3029.
69. Yellin, M.J., Sinning, J., Covey, L.R., Sherman, W., Lee, J.J., Glickman-Nir, E., Sippel, K.C., Rogers, J., Cleary, A.M., Parker, M., Chess, L. and Lederman, S. (1994) T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulalory activity. J Immunol, 153, 666-674.
70. Ranheim, E.A. and Kipps, T.J. (1993) Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J. Exp. Med, 177, 925-935.
71. Watts, T., Alaverdi, N., Wade, W. and Linsley, P. (1993) Induction of costimulatory molecule B7 in M12 B lymphomas by cAMP or MHC restricted T cell interaction. J. Immunol, 150, 2192-2202.
72. Nabavi, N., Freeman, G., Gault, A., Godfrey, D., Nadler, M. and Glimcher, L. (1992) Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature, 360, 266-268.
73. Vallé, A., Aubry, J.-P., Durand, I. and Banchereau, J. (1991) IL-4 and IL-2 up-regulate the expression of antigen B7, the B cell counterstructure to T cell CD28: an amplification mechanism for T-B cell interactions. Int. Immunol, 3, 229-235.
74. Stack, R.M., Lenschow, D.J., Gray, G.S., Bluestone, J.A. and Fitch, F.W. (1994) IL-4 treatment of small splenic B cells induces costimulatory molecules B7-1 and B7-2. J Immunol, 152, 5723-5733.
75. Suda, T., Takahashi, T., Golstein, P. and Nagata, S. (1993) Molecular cloning and expression of the Fas ligand, a novel member of the Tumor Necrosis Factor family. Cell, 75, 1169-1178.
76. Yonehara, S., Ishii, A. and Yonehara, M. (1989) A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med, 169, 1747-1756.
77. Trauth, B.C., Klas, C., Peters, A.M.J., Matzku, S., Möller, P., Falk, W., Debatin, K.M. and Krammer, P.H. (1989) Monoclonal antibody mediated tumor regression by induction of apoptosis. Science, 245, 301-305.
78. Lowin, B., Hahne, M., Mattmann, C. and Tschopp, J. (1994) Cytolytic T-cell cytotoxicity is mediated through perform and Fas lytic pathways. Nature, 370, 650-652.
79. Kagi, D., Vignaux, F., Ledermann, B., Burki, K., Depraetere, V., Nagata, S., Hengartner, H. and Golstein, P. (1994) Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science, 265, 528-530.
80. Rathmell, J.C., Townsend, S.E., Xu, J.C., Flavell, R.A. and Goodnow, C.C. (1996) Expansion or elimination of B cells in vivo: dual roles for CD40 and Fas (CD95) ligands modulated by the B cell antigen receptor. Cell, 87, 319-329.
81. Garrone, P., Neidhardt, E.M., Garcia, E., Galibert, L., van Kooten, C. and J., B. (1995) Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J. Exp. Med, 182, 1265-1273.
82. Schattner, E.J., Elkon, K.B., Yoo, D.H., Tumang, J., Krammer, P.H., Crow, M.K. and Friedman, S.M. (1995) CD40 ligation induces apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the apo-1/Fas pathway. J Exp Med, 182, 1557-1565.
83. Plumas, J., Jacob, M.C., Chaperot, L., Molens, J.P., Sotto, J.J. and Bensa, J.C. (1998) Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1 (-mediated apoptosis. Blood, 91, 2875-2885.
84. Möller, P., Henne, C., Leithäuser, F., Eichelmann, A., Schmidt, A., Brüderlein, S., Dhein, J. and Krammer, P. (1993) Coregulation of the APO-1 antigen with intercellular adhesion molecule-1 (CD54) on tonsillar B cells and coordinate expression in follicular center B cells and in follicle center and mediastinal B-cell lymphomas, Blood, 81, 2067-2075.
85. Lagresle, C., Mondiere, P., Bella, C., Krammer, P.H. and Defrance, T. (1996) Concurrent engagement of CD40 and the antigen receptor protects naive and memory human B cells from APO-1/Fas mediated apoptosis. J. Exp. Med, 183, 1377-1388.
86. Kondo, E., Yoshino, T., Yamadori, I., Matsuo, Y., Kawasaki, N., Minowada, J. and Akagi, T. (1994) Expression of bcl-2 protein and Fas antigen in non-Hodgkin's lymphomas. Am J Pathol, 145, 330-337.
87. Yang, E. and Korsmeycr, S.J. (1996) Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood, 88, 386-401.
88. Xerri, L., Parc, P., Brousset, P., Schlaifer, D., Hassoun, J., Reed, J.C. and Krajewski, S. (1996) Predominant expression of the long isoform of Bcl-X (Bcl-xL) in human lymphomas. Brit. J. Haematol, 92, 900-906.
89. Schneider, T.J., Grillot, D., Foole, L.C., Nunez, G.E. and Rothstein, T.L. (1997) Bcl-x protects primary B cells against Fas-mediated apoptosis, J Immunol, 159, 4834-4839.
90. Xerri, L., Devilard, E., Bouabdallah, R., Hassoun, J., Chaperot, L., Birg, F. and Plumas, J. (1999) Quantitative analysis detects ubiquitous expression of apoptotic regulators in B cell non-Hodgkin's lymphomas. Leukemia, 13, 1548-1553.
91. Okura, T., Gong, L., Kamitani, T., Wada, T., Okura, I., Wei, C.-F., Chang, H.-M. and Yeh, E.T.H. (1996) Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J. Immunol, 157, 4277-4281.
92. Kataoka, T., Schroter, M., Hahne, M., Schneider, P., Irmler, M., Thome, M., Froelich, C. J. and Tschopp, J. (1998) FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol, 161, 3936-3942.
93. Schneider, T.J., Fischer, G.M., Donohoe, T.J., Colarusso, T.P. and Rothstein, T.L. (1999) A novel gene coding for a Fas inhibitory molecule (FAIM) isolated from inducibly Fas-resistant B lymphocytes. J. Immunol, 189, 949-955.
94. Kudoh, S., Wang, Q., Hidalgo, O.F., Rayman, P., Tubbs, R.R., Edinger, M.G., Kolenko, V., Panuto, J., Bukowski, R. and Finke, J.H. (1995) Responses to T cell receptor CD3 and interleukin-2 receptor stimulation are altered in T cells from B cell non hodgkin's lymphomas. Cancer Immunol Immunother, 41, 175-184.
95. Wang, Q., Stanley, J., Kudoh, S., Myles, J., Kolenko, V., Yi, T.L., Tubbs, R., Bukowski, R. and Finke, J. (1995) T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present. J Immunol, 155, 1382-1392.
96. Schwartzentruber, D.J., Steler-Stevenson, M., Rosenberg, S.A. and Topalian, S.L. (1993) Tumor-infiltrating lymphocytes from select B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-α in response to autologous tumor stimulation. Blood, 82, 1204-1211.
97. Trinchieri, G. and Scott, P. (1994) The role of interleukin 12 in the immune response, disease and therapy. Immunol Today, 15, 460-463.
98. Zeh, H.J., Hurd, S., Storkus, W.J. and Lotze, M.T. (1993) Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors - implications for the immunotherapy of cancer. J Immunother, 14, 155-161.
99. Durum, S.K., Schmidt, J.A. and Oppenheim, J.J. (1985) Interleukin 1: an immunological perspective. Ann. Rev. Immunol, 3, 263-287.
100. Chaperot, L., Delfeau-Larue, M.-H., Jacob, M.-C., Molens, J.-P., Roussel, B., Agrawal, S., Farcet, J.-P., Gressin, R., Sotto, J.-J., Bensa, J.-C. and Plumas, J. (1999) Differentiation of antitumor-specific cytotoxic T lymphocytes from autologous tumor infiltrating lymphocytes in non-Hodgkin's lymphomas. Exp. Hematol., 27, 1185-1193.
101. Hirohata, S. (1999) Human Th1 responses driven by IL-12 are associated with enhanced expression of CD40 ligand. Clin Exp Immunol, 115, 78-85.
102. Peng, X., Remacle, J.E., Kasran, A., Huylebroeck, D. and Ceuppens, J.L. (1998) IL-12 up-regulates CD40 Ligand (CDl54) expression on human T cells. J. Immunol, 160, 1166-1172.
103. Schultze, J.L., Seamon, M.J., Michalak, S., Gribben, J.G. and Nadler, L.M. (1997) Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood, 89, 3806-3816.
104. Rathmell, J.C., Cooke, M.P., Ho, W.Y., Grein, J., Townsend, S.E., Davis, M.M. and Goodnow, C.C. (1995) CD95 (fas) dependent elimination of self reactive B cells upon interaction with CD4(+) T cells. Nature, 376, 181-184.
105. Voorzanger, N., Touitou, R., Garcia, E., Delecluse, H.J., Rousset, F., Joab, I., Favrot, M.C. and Blay, J.Y. (1996) Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res, 56, 5499-5505.
106. Moore, K.W., O'Garra, A., de Waal Malefyt, R., Vieira, P. and Mosmann, T.R. (1993) Interleukin-10. Annu Rev Immunol, 11, 165-190.
107. Taga, K., Mostowski, H. and Tosato, G. (1993) Human interleukin-10 can directly inhibit T-cell growth. Blood, 81, 2964-2971.
108. Steinbrink, K., Jonuleit, H., Muller, G., Schuler, G., Knop, J. and Enk, A.H. (1999) Interleukin-10-treated human dendritic cells induce a melanoma-antigen- specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood, 93, 1634-1642.
109. Buelens, C., Willems, F., Delvaux, A., Pierurd, G., Delville, J.P., Velu, T. and Goldman, M. (1995) Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells. Eur J Immunol, 25, 2668-2672.
110. Bonnefoix, T., Claret, E., Piccini, M.P., Jacob, M.C., Zheng, X. and Sotto, J.J. (1991) Detection, isolation and functional studies of CD25+ T cells in lymph nodes involved by B-cell non-Hodgkin's lymphomas. Scand. J. Immunol, 34, 91-100.
111. Diaz, J.I., Edinger, M.G., Stoler, M.H. and Tubbs, R.R. (1991) Activated T-cell subsets in begnin lymphoid hyperplasias and B-cells non-Hodgkin's lymphomas. Am. J. Pathol, 139, 503-509.
112. Jacob, M.C., Fahre, M., LeMarc'Hadour, F., Sotto, M.F., Bonnefoix, T., Sotto, J.J. and Bensa, J.C. (1992) CD45RA expression by CD4 T lymphocytes in tumors invaded by B-cell non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD). Am. J. Hematol, 39, 45-51.
113. Agrawal, S., Marquet, J., Delfau Larue, M.H., Copie Bergman, C., Jouault, H., Reyes, F., Bensussan, A. and Farcet, J.P. (1998) CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs. J Clin Invest, 102, 1715-1723.
114. Jacob, M.C., Piccini, M.P., Bonnefoix, T., Sotto, M.F., Coudere, P., Bensa, J.C. and Sotto, J.J. (1990) T lymphocytes from invaded lymph nodes in patients with B-cell-derived non-Hodgkin's lymphoma: reactivity toward the malignant clone. Blood, 75, 1154-1162.
115. Shi, I., Bonnefoix, T., Heuzelevacon, F., Jacob, M.C., Leroux, D., Gressin, R., Sotto, M.F., Chaffanjon, P., Bensa, J.C. and Sotto, J.J. (1995) Autotumour reactive T-cell clones among tumour-infiltrating T lymphocytes in B-cell non-hodgkin's lymphomas. Br J Haematol, 90, 837-843.
116. Umetsu, D.T., Esserman, L., Donlon, T.A., DeKruyff, R.H. and Levy, R. (1990) Induction of proliferation of human follicular (B type) lymphoma cells by cognate interaction with CD4+ T cell clones, J. Immunol, 144, 2550-2557.
117. Martin, I., Bonnefoix, T., Roucard, C., Perron, P., Lajmanovich, A., Moine, A., Leroux, D., Sotto, J.J. and Garban, F. (1999) Role of autologous CD4+ T cell clones in human B non-Hodgkin's lymphoma: aborted activation and G1 blockade induced by ceel-cell contact. Eur. J. Immunol, in press.
118. Rohrer, J.W. and Coggin, J.H. (1995) CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. J Immunol, 155, 5719-5727.
119. Schwaller, J., Tobler, A., Niklaus, G., Hurwitz, N., Hennig, I., Fey, M.F. and Borisch, B. (1995) Interleukin-12 expression in human lymphomas and nonneoplastic lymphoid disorders. Blood, 85, 2182-2188.